Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1998 Apr;51(4):294–298. doi: 10.1136/jcp.51.4.294

Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer.

M V González 1, V Alvarez 1, M F Pello 1, M J Menéndez 1, C Suárez 1, E Coto 1
PMCID: PMC500672  PMID: 9659241

Abstract

AIMS: To analyse the allele frequencies of DNA polymorphisms at the genes for cytochromes P450IIE1 and P450IID6, N-acetyltransferase-2, and glutathione S-transferase-M1 in patients with head and neck squamous cell carcinoma, in an attempt to define genetic factors involved in the susceptibility to this cancer, which is strongly associated with tobacco consumption. METHODS: Determination of restriction fragment length polymorphism (RFLP) at cytochromes P450IIE1/P450IID6 and NAT2 genes, and the presence of homozygous deletion of the GSTM1 gene, in 200 controls and 75 head and neck cancer patients. Allelic frequencies between the two groups were compared using a chi 2 test, and odds ratio with 95% confidence intervals were calculated. RESULTS: There was no evidence of an association between alleles of CYP2D6 and CYP2E1 and head and neck cancer in our population. Similarly, frequencies of individuals lacking the GSTM1 gene did not differ between controls and patients. However, individuals with the NAT2-SA phenotype were at higher risk of developing head and neck cancer. The frequencies of the most common SA genotype (homozygous for the NAT2*5 allele) were higher in patients than in controls (27% v 15%, respectively). Slow acetylators homozygous for the NAT2*6 allele, the second most common SA allele, were also more common in patients than in controls (11% v 5%, respectively). CONCLUSIONS: Slow NAT2 activity is a risk factor possibly leading to the development of head and neck cancer in response to tobacco carcinogens.

Full text

PDF
294

Images in this article

297Image
on p.297

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agúndez J. A., Ledesma M. C., Benítez J., Ladero J. M., Rodríguez-Lescure A., Díaz-Rubio E., Díaz-Rubio M. CYP2D6 genes and risk of liver cancer. Lancet. 1995 Apr 1;345(8953):830–831. doi: 10.1016/s0140-6736(95)92965-7. [DOI] [PubMed] [Google Scholar]
  2. Ambrosone C. B., Freudenheim J. L., Graham S., Marshall J. R., Vena J. E., Brasure J. R., Michalek A. M., Laughlin R., Nemoto T., Gillenwater K. A. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA. 1996 Nov 13;276(18):1494–1501. [PubMed] [Google Scholar]
  3. Blum M., Demierre A., Grant D. M., Heim M., Meyer U. A. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci U S A. 1991 Jun 15;88(12):5237–5241. doi: 10.1073/pnas.88.12.5237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Caporaso N., Hayes R. B., Dosemeci M., Hoover R., Ayesh R., Hetzel M., Idle J. Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype. Cancer Res. 1989 Jul 1;49(13):3675–3679. [PubMed] [Google Scholar]
  5. Cascorbi I., Brockmöller J., Mrozikiewicz P. M., Bauer S., Loddenkemper R., Roots I. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res. 1996 Sep 1;56(17):3961–3966. [PubMed] [Google Scholar]
  6. Cascorbi I., Drakoulis N., Brockmöller J., Maurer A., Sperling K., Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet. 1995 Sep;57(3):581–592. [PMC free article] [PubMed] [Google Scholar]
  7. Comstock K. E., Sanderson B. J., Claflin G., Henner W. D. GST1 gene deletion determined by polymerase chain reaction. Nucleic Acids Res. 1990 Jun 25;18(12):3670–3670. doi: 10.1093/nar/18.12.3670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Drózdz M., Gierek T., Jendryczko A., Pilch J., Piekarska J. N-acetyltransferase phenotype of patients with cancer of the larynx. Neoplasma. 1987;34(4):481–484. [PubMed] [Google Scholar]
  9. Gonzalez F. J. Genetic polymorphism and cancer susceptibility: fourteenth Sapporo Cancer Seminar. Cancer Res. 1995 Feb 1;55(3):710–715. [PubMed] [Google Scholar]
  10. González M. V., Pello M. F., López-Larrea C., Suárez C., Menéndez M. J., Coto E. Deletion and methylation of the tumour suppressor gene p16/CDKN2 in primary head and neck squamous cell carcinoma. J Clin Pathol. 1997 Jun;50(6):509–512. doi: 10.1136/jcp.50.6.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. González M. V., Pello M. F., López-Larrea C., Suárez C., Menéndez M. J., Coto E. Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck. Clin Cancer Res. 1995 Sep;1(9):1043–1049. [PubMed] [Google Scholar]
  12. Hayes J. D., Wolf C. R. Molecular mechanisms of drug resistance. Biochem J. 1990 Dec 1;272(2):281–295. doi: 10.1042/bj2720281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Heckbert S. R., Weiss N. S., Hornung S. K., Eaton D. L., Motulsky A. G. Glutathione S-transferase and epoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers. J Natl Cancer Inst. 1992 Mar 18;84(6):414–422. doi: 10.1093/jnci/84.6.414. [DOI] [PubMed] [Google Scholar]
  14. Hein D. W. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta. 1988 Aug 3;948(1):37–66. doi: 10.1016/0304-419x(88)90004-2. [DOI] [PubMed] [Google Scholar]
  15. Hein D. W., Doll M. A., Rustan T. D., Ferguson R. J. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res. 1995 Aug 15;55(16):3531–3536. [PubMed] [Google Scholar]
  16. Hein D. W., Ferguson R. J., Doll M. A., Rustan T. D., Gray K. Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. Hum Mol Genet. 1994 May;3(5):729–734. doi: 10.1093/hmg/3.5.729. [DOI] [PubMed] [Google Scholar]
  17. Hickman D., Risch A., Buckle V., Spurr N. K., Jeremiah S. J., McCarthy A., Sim E. Chromosomal localization of human genes for arylamine N-acetyltransferase. Biochem J. 1994 Feb 1;297(Pt 3):441–445. doi: 10.1042/bj2970441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hirvonen A., Husgafvel-Pursiainen K., Anttila S., Karjalainen A., Vainio H. The human CYP2E1 gene and lung cancer: DraI and RsaI restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis. 1993 Jan;14(1):85–88. doi: 10.1093/carcin/14.1.85. [DOI] [PubMed] [Google Scholar]
  19. Ilett K. F., David B. M., Detchon P., Castleden W. M., Kwa R. Acetylation phenotype in colorectal carcinoma. Cancer Res. 1987 Mar 1;47(5):1466–1469. [PubMed] [Google Scholar]
  20. Kato S., Shields P. G., Caporaso N. E., Hoover R. N., Trump B. F., Sugimura H., Weston A., Harris C. C. Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res. 1992 Dec 1;52(23):6712–6715. [PubMed] [Google Scholar]
  21. Risch A., Wallace D. M., Bathers S., Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet. 1995 Feb;4(2):231–236. doi: 10.1093/hmg/4.2.231. [DOI] [PubMed] [Google Scholar]
  22. Seidegård J., Pero R. W., Miller D. G., Beattie E. J. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis. 1986 May;7(5):751–753. doi: 10.1093/carcin/7.5.751. [DOI] [PubMed] [Google Scholar]
  23. Smith C. A., Gough A. C., Leigh P. N., Summers B. A., Harding A. E., Maraganore D. M., Sturman S. G., Schapira A. H., Williams A. C., Maranganore D. M. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet. 1992 Jun 6;339(8806):1375–1377. doi: 10.1016/0140-6736(92)91196-f. [DOI] [PubMed] [Google Scholar]
  24. Smith C. A., Smith G., Wolf C. R. Genetic polymorphisms in xenobiotic metabolism. Eur J Cancer. 1994;30A(13):1921–1935. doi: 10.1016/0959-8049(94)00382-f. [DOI] [PubMed] [Google Scholar]
  25. Vineis P., Bartsch H., Caporaso N., Harrington A. M., Kadlubar F. F., Landi M. T., Malaveille C., Shields P. G., Skipper P., Talaska G. Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature. 1994 May 12;369(6476):154–156. doi: 10.1038/369154a0. [DOI] [PubMed] [Google Scholar]
  26. Wolf C. R., Smith C. A., Bishop T., Forman D., Gough A. C., Spurr N. K. CYP2D6 genotyping and the association with lung cancer susceptibility. Pharmacogenetics. 1994 Apr;4(2):104–106. doi: 10.1097/00008571-199404000-00008. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES